Aptose Biosciences (APTO) announced the publication of preclinical data for Aptose’s lead hematology compound tuspetinib in Cancer Research ...

"In this high-risk population with relapsed and refractory disease and extensive prior therapy, pirtobrutinib demonstrated ...

Moleculin Biotech shares are trading higher on Wednesday after the company announced the online publication of preclinical ...

A fixed duration combination of venetoclax with acalabrutinib, with or without obinutuzumab, was superior to standard ...

A shorter duration of venetoclax treatment for newly diagnosed acute myeloid leukemia (AML) may enhance efficacy and reduce ...

Developments in chronic lymphocytic leukemia (CLL) this year included the first CAR T-cell therapy approval for the chronic ...

Revumenib, venetoclax, and ASTX727 (a fixed-dose combination of decitabine and cedazuridine) demonstrated efficacy in patients with relapsed or refractory AML.

Long-term data support the safety and efficacy of venetoclax (Venclexta) and obinutuzumab (Gazyva) in chronic lymphocytic ...

About a third of patients with diffuse large B cell lymphoma (DLBCL), a fast-growing form of lymphoma, will see their disease ...

Three clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated significant ...

SAN DIEGO -- A fixed-duration oral combination significantly reduced the risk of disease progression or death compared with ...